Summary
Johnson & Johnson, through its subsidiary ETHICON, Inc., announced on May 9, 2006, the completion of its acquisition of Vascular Control Systems, Inc. This privately held company specializes in medical devices for treating fibroids and controlling bleeding in obstetrics and gynecology. The acquisition signals JNJ's strategic interest in expanding its medical device portfolio within the women's health and surgical sectors. While specific financial terms were not disclosed, the company anticipates a one-time, after-tax charge of approximately $90 million, or $0.03 per share, primarily due to in-process research and development write-offs. Investors should note this charge as a non-recurring item impacting near-term earnings. The strategic rationale behind the acquisition is likely to enhance ETHICON's product offerings and market presence in these specialized medical device areas.
Key Highlights
- 1Johnson & Johnson subsidiary ETHICON acquired Vascular Control Systems, Inc. on May 9, 2006.
- 2Vascular Control Systems, Inc. focuses on medical devices for fibroid treatment and obstetric/gynecologic bleeding control.
- 3The acquisition expands ETHICON's presence in women's health and surgical devices.
- 4No specific transaction terms were disclosed publicly.
- 5A one-time, after-tax charge of approximately $90 million ($0.03 per share) is expected.
- 6The charge is primarily attributed to in-process R&D write-offs.